ACELYRIN, INC.

Good day and thank you for standing by. Welcome to the Celeron Q3 2023 earnings conference call. At this time, all participants are in listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Tyler Marciniak, Vice President of Investor Relations, Communications, and Corporate Operations. Please go ahead.

Thank you, Operator. Good afternoon, everyone, and thank you for joining us.

Before we begin, I'd like to remind the audience that this conference call will contain forward-looking statements, such as those related to progress of our clinical trials and anticipated data readouts, our future financial and operating results and investments, and our ability to commercialize our product candidates. These forward-looking statements involve risks and uncertainties that could cause our actual results and events to differ materially. We urge you to review the risk factors section of our Form 10-Q for the quarter ended June 30, 2023, filed at the SEC, and also available on our website at acelerin.com, along with statements in today's press release and our slide presentation, which identify certain factors that could cause our actual results, performance, and events to differ materially. Additionally, these statements are based on information available to us today, November 7, 2023, and we undertake no obligation to update them as circumstances may change. Joining us on today's call are Dr. Xiaoli Lin, our founder and CEO, and Gil Labroucherie, our chief financial officer. I will now turn the call over to Dr. Lin. Shall we?